Public Market Listing
1877HKEX
Live quotes, historical charts, and market capitalization for Shanghai Junshi Bioscience are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(6 total)
6Total Assets
1Approved
1Phase 3 / Filed
4Phase 1–2 / Early
3Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Approved | PD-1Monoclonal antibody | Non-Small Cell Lung CancerNasopharyngeal Carcinoma | |
Ongericimab(Junshida) | Phase 3 | PCSK9Monoclonal antibody | Atherosclerotic Cardiovascular Disease |
| Phase 2 | PD-1 + VEGFAMultispecific antibody | Non-Small Cell Lung Cancer | |
| Phase 2 | EGFR + HER3Antibody–drug conjugate | Non-Small Cell Lung Cancer | |
| Phase 1/2 | EGFRSmall molecule | Non-Small Cell Lung Cancer | |
| Phase 1 | PD-1 (anchoring) / IL-2Rβγ (cis-activation)Small molecule | Non-Small Cell Lung Cancer |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.